ArriVent BioPharma (NASDAQ: AVBP) recently received a number of ratings updates from brokerages and research firms:
- 10/27/2026 – ArriVent BioPharma had its price target raised by Guggenheim from $18.00 to $30.00. They now have a “buy” rating on the stock.
- 10/26/2026 – ArriVent BioPharma was given a new $21.00 price target by Truist Financial.
- 10/26/2026 – ArriVent BioPharma had its “outperform” rating reaffirmed by Oppenheimer. They now have a $25.00 price target on the stock.
- 10/20/2026 – ArriVent BioPharma had its price target lowered by B. Riley Financial from $45.00 to $29.00. They now have a “buy” rating on the stock.
- 10/18/2026 – ArriVent BioPharma was upgraded by Wall Street Zen from “strong sell” to “sell”.
- 10/16/2026 – ArriVent BioPharma had its “buy” rating reaffirmed by BTIG Research. They now have a $29.00 price target on the stock.
- 10/15/2026 – ArriVent BioPharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 10/10/2026 – ArriVent BioPharma was downgraded by Wall Street Zen from “sell” to “strong sell”.
- 10/8/2026 – ArriVent BioPharma had its price target lowered by HC Wainwright from $47.00 to $27.00. They now have a “buy” rating on the stock.
- 10/7/2026 – ArriVent BioPharma had its price target lowered by Guggenheim from $45.00 to $18.00. They now have a “buy” rating on the stock.
- 10/7/2026 – ArriVent BioPharma had its price target lowered by BTIG Research from $42.00 to $29.00. They now have a “buy” rating on the stock.
- 10/7/2026 – ArriVent BioPharma had its price target lowered by Citigroup from $40.00 to $20.00. They now have a “buy” rating on the stock.
- 10/7/2026 – ArriVent BioPharma had its price target lowered by JonesTrading from $45.00 to $22.00. They now have a “buy” rating on the stock.
- 10/6/2026 – ArriVent BioPharma had its price target lowered by Truist Financial from $45.00 to $18.00. They now have a “buy” rating on the stock.
- 10/6/2026 – ArriVent BioPharma was given a new $18.00 price target by Jefferies Financial Group.
- 9/22/2026 – ArriVent BioPharma had its “overweight” rating reaffirmed by Cantor Fitzgerald.
ArriVent BioPharma Stock Performance
Shares of AVBP opened at $13.35 on Tuesday. The stock’s 50-day simple moving average is $24.44 and its 200 day simple moving average is $26.83. The stock has a market capitalization of $658.29 million, a price-to-earnings ratio of -3.69 and a beta of 1.34. ArriVent BioPharma, Inc. has a 52-week low of $11.36 and a 52-week high of $35.83.
ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.06). On average, research analysts forecast that ArriVent BioPharma, Inc. will post -4.04 earnings per share for the current fiscal year.
ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision oncology therapies for patients with genetically defined cancers. The company’s primary focus is on targeted treatments for non-small cell lung cancer (NSCLC), particularly tumors driven by mutations in the epidermal growth factor receptor (EGFR) gene.
ArriVent’s lead product candidate is furmonertinib, an oral, irreversible EGFR tyrosine kinase inhibitor designed to target a range of EGFR mutations, including common mutations and exon 20 insertion mutations.
Read More
- Five stocks we like better than ArriVent BioPharma
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AIāThese 5 Stocks Are Getting Paid
Receive News & Ratings for ArriVent BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.
